Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.
about
Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis modelIn vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals19F magnetic resonance imaging of perfluorocarbons for the evaluation of response to antibiotic therapy in a Staphylococcus aureus infection modelEngineering an enhanced, thermostable, monomeric bacterial luciferase gene as a reporter in plant protoplastsRapid dissemination of Francisella tularensis and the effect of route of infection.Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.Near-infrared fluorescence imaging as an alternative to bioluminescent bacteria to monitor biomaterial-associated infectionsQuantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging.Noninvasive biophotonic imaging for monitoring of catheter-associated urinary tract infections and therapy in mice.Efficacy of enrofloxacin in a mouse model of sepsis.Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response.In vivo monitoring of Staphylococcus aureus biofilm infections and antimicrobial therapy by [18F]fluoro-deoxyglucose-MicroPET in a mouse model.Noninvasive biophotonic imaging for studies of infectious disease.Tn5/7-lux: a versatile tool for the identification and capture of promoters in gram-negative bacteria.Scaffold-based anti-infection strategies in bone repair.Non invasive real-time monitoring of bacterial infection & therapeutic effect of anti-microbials in five mouse models.An organoselenium compound inhibits Staphylococcus aureus biofilms on hemodialysis catheters in vivo.Simvastatin is protective during Staphylococcus aureus pneumoniaRapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tractCombinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infectionA destabilized bacterial luciferase for dynamic gene expression studies.In vitro and in vivo validation of ligA and tarI as essential targets in Staphylococcus aureus.Comparative Efficacies of Tedizolid Phosphate, Linezolid, and Vancomycin in a Murine Model of Subcutaneous Catheter-Related Biofilm Infection Due to Methicillin-Susceptible and -Resistant Staphylococcus aureus.Development of real-time in vivo imaging of device-related Staphylococcus epidermidis infection in mice and influence of animal immune status on susceptibility to infection.In vivo imaging of bioluminescent Escherichia coli in a cutaneous wound infection model for evaluation of an antibiotic therapy.Foreign Body Infection Models to Study Host-Pathogen Response and Antimicrobial Tolerance of Bacterial Biofilm.In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.A bioluminescent Pseudomonas aeruginosa wound model reveals increased mortality of type 1 diabetic mice to biofilm infection.Bifunctional antimicrobial conjugates and hybrid antimicrobials.Establishment of a real-time, quantitative, and reproducible mouse model of Staphylococcus osteomyelitis using bioluminescence imaging.Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo.Investigation of four (99m)Tc-labeled bacteriophages for infection-specific imaging.Use of a bioluminescent Pseudomonas aeruginosa strain within an in vitro microbiological system, as a model of wound infection, to assess the antimicrobial efficacy of wound dressings by monitoring light production.The risk of biomaterial-associated infection after revision surgery due to an experimental primary implant infection.Staphylococcus aureus promoter-lux reporters for drug discovery.Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.Bacteriophage-Derived Peptidase CHAP(K) Eliminates and Prevents Staphylococcal Biofilms.Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model.Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis.
P2860
Q24558684-4014AA3A-0F14-49D6-BCEE-88295C53C211Q27006069-3FB39709-00FF-4D2E-A27F-8B6B10A21417Q27318705-08EE1FA9-A1D1-44C4-812A-EBE15875879AQ28543460-A02A0FAE-6EB3-472F-9167-3207F634F452Q30486333-74B8ED5E-5CCB-4B10-A832-E7EC41FEF60AQ30574330-D8272346-6C6C-4DC9-ADC3-C1A7CEEEA543Q33700191-DB63EDC1-3D1F-4937-AD80-4B2A231B8F36Q33762541-D78B0FF9-EB1C-4243-99AF-10E03D803353Q33883442-62E211F2-06CC-4A27-9598-578E176C7B0EQ33960627-93F5470B-CF1B-4479-B4A6-2629AD7FCC3CQ34194556-4F5D4F59-5E57-4AAC-8DF4-286B6DAECFF9Q34596570-EC044ECA-E979-4F5C-9853-991704287D5EQ34886067-954D594E-D7FE-4837-B4C8-D05703D9D303Q35083368-E72F1B22-EDD2-4862-8856-1FFF45F0B078Q35235414-A39F66A7-D7BD-4E73-B386-9358FE7956DAQ35646918-A88D8383-33F4-4745-99E5-9AA4DD9FE8AEQ35689281-5D457F43-107A-4587-AAEC-61C4C1230492Q35747672-4BB30CB5-EDD6-4BF0-B593-5C51B0EFD32BQ35759049-A7C1DA74-2D41-4F3A-99B3-27C3310930F4Q36082306-19598F86-F895-485F-826B-950CF891BC8BQ36292752-1267B7E7-BFB0-4A6D-91EF-4F03A63696FBQ36869653-256A1105-F9E4-4721-944B-7DB42F475F18Q36993458-565B48A5-6402-4D48-8697-5922772741D2Q37120160-1459B170-370D-492B-9EA7-C44CA66A21E1Q37390336-53C1E321-5CD8-418E-A91E-C8DAF728C14DQ37489613-E596C043-1669-47FC-88A3-20A3E979F6CFQ38792881-15C8E829-D7A3-49E2-9B05-AC0A7DE2035EQ39686067-244140F8-0FE1-45F4-8353-57BD5D2AF689Q40136321-ABF28427-5A81-4FEE-BD92-3A8790A0E088Q40203926-42E99087-3B4D-4B5A-847E-47EBA04C7EB2Q40603111-0D0B187B-2C52-4F53-9BAE-9A56F1A7DCA7Q40882862-A1D806DE-D508-44C5-8650-07233BD2597BQ42133096-BF0FC042-9821-4829-B151-AC46800116C6Q42627504-45C415E1-E86A-411B-ADFD-85F78CD96EDEQ42926768-FBC51A48-7A54-4021-8F9C-2E61AB719D45Q42981005-3490C1E4-8D5F-4F40-8F84-959187601962Q43169904-E8CA0D8A-C174-4849-A14A-CF4E6DA0A754Q43245858-DB61FD43-FE1C-4BCB-AFE6-B1480CA8AF79Q46279362-02FA25A4-93C3-4908-A427-40427CCCBA64Q46881245-0F6531D3-5FA6-4AC8-B151-325C6ECA2732
P2860
Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Rapid direct method for monito ...... f bacterial biofilm infection.
@ast
Rapid direct method for monito ...... f bacterial biofilm infection.
@en
type
label
Rapid direct method for monito ...... f bacterial biofilm infection.
@ast
Rapid direct method for monito ...... f bacterial biofilm infection.
@en
prefLabel
Rapid direct method for monito ...... f bacterial biofilm infection.
@ast
Rapid direct method for monito ...... f bacterial biofilm infection.
@en
P2093
P2860
P1476
Rapid direct method for monito ...... f bacterial biofilm infection.
@en
P2093
Jagath L Kadurugamuwa
Kevin P Francis
Pamela R Contag
Richard Kimura
Tony Purchio
P2860
P304
P356
10.1128/AAC.47.10.3130-3137.2003
P407
P577
2003-10-01T00:00:00Z